DISTONIYA - ZAMONAVIY DAVOLASH TAKTIKASI
Keywords:
distonia, botulinotherapia.Abstract
Ushbu maqolada distoniya muammosi tadqiqotchilar uchun yorqin va g‘ayrioddiy klinik ko‘rinish, genlar funksiyalari va kasallik patogenezining sensorimotor mexanizmlarini o‘rganish imkoniyatlari, shuningdek, target terapiya – botulinoterapiya in’yeksiyasining dramatik ta’sir nuqtai nazaridan motor buzilishlarining eng "jozibali" shakli bo‘lib qolgani haqida so‘z yuritiladi.
References
1. Albanese A., Asmus F., Bhatia K.P., Elia A.E., Elibol B., Filippini G., Gasser T., Krauss J.K., Nardocci N., Newton A., Valls-Solé J. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18(1): 5–18.
2. Orlova O.R. Fokalnie distonii: klinika, patogenez, lechenie s ispolzovaniem toksina botulizma: Avtoref. dis. …dokt. med. nauk. M., 2000; 48c.
3. Simpson D.M., Hallett M., Ashman E.J., Comella C.L., Green M.W., Gronseth G.S., Armstrong M.J., Gloss D., Potrebic S., Jankovic J., Karp B.P., Naumann M., So Y.T., Yablon S.A. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2016; 86(19): 1818–1826.
4. Albanese A., Barnes M.P., Bhatia K.P., Fernandez-Alvarez E., Filippini G., Gasser T., Krauss J.K., Newton A., Rektor I., Savoiardo M., Valls-Solè J. A systematic review on the diagnosis and treatmentof primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13(5): 433–444.
5. Bressman S.B., Raymond D., Fuchs T., Heiman G.A., Ozelius L.J., Saunders-Pullman R. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009; 8(5): 441–446.
6. Valente E.M., Edwards M.J., Mir P., DiGiorgio A., Salvi S., Davis M., Russo N., Bozi M., Kim H.T., Pennisi G., Quinn N., Dallapiccola B., Bhatia K.P. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology 2005; 64(4): 737–739.
7. Robinson R., McCarthy G.T., Bandmann O., Dobbie M., Surtees R., Wood N.W. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry 1999; 66(1): 86–89.
8. Klein C., Friedman J., Bressman S., Vieregge P., Brin M.F., Pramstaller P.P., De Leon D., Hagenah J., Sieberer M., Fleet C., Kiely R., Xin W., Breakefield X.O., Ozelius L.J., Sims K.B. Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. Genet Test 1999; 3(4): 323–328.
9. Djarmati A., Schneider S.A., Lohmann K., Lohmann K., Winkler S., Pawlack H., Hagenah J., Brüggemann N., Zittel S., Fuchs T., Raković A., Schmidt A., Jabusch H.C., Wilcox R., Kostić V.S., Siebner H., Altenmüller E., Münchau A., Ozelius L.J., Klein C. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009; 8(5): 447–452.
10. Albanese A., Lalli S. Is this dystonia? Mov Disord 2009; 24(12): 1725–1731.
11. Timerbaeva S.L. Fokalnie i segmentarnie formi pervichnoy distonii: klinicheskie, patofiziologicheskie i molekulyarno-geneticheskie aspekti: Avtoref. dis. … dokt. med. nauk. M., 2012; 51c.
12. Azbuka botulinoterapii. Pod red. Timerbaevoy S.L. M.: Prakticheskaya medisina 2014; 441c.
13. Consky E.S., Basinski A., Belle L., Ranawaya R., Lang A.E. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability (abstract). Neurology 1990; 40: 445.
14. Orlova O.R., Yaxno N.N. Primenenie botoksa (toksina botulizma tipa A) v klinicheskoy praktike. Rukovodstvo dlya vrachey. M.: Katalog 2001; 201s.
15. Bressman S.B., Sabatti C., Raymond D., de Leon D., Klein C., Kramer P.L., Brin M.F., Fahn S., Breakefield X., Ozelius L.J., Risch N.J. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000; 54(9): 1746–1752. 16. Rutledge J.N., Hilal S.K., Silver A.J., Defendini R., Fahn S. Magnetic resonance imaging of dystonic states. Adv Neurol 1988; 50: 265–275.
17. Meunier S., Lehericy S., Garnero L., Vidailhet M. Dystonia: lessons from brain mapping. Neuroscientist 2003; 9(1): 76–81.
18. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., Jankovic J., Karp B., Ludlow C.L., Miyasaki J.M., Naumann M., So Y.; Therapeutics and Technology Assessment Subcommittee of the American Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidencebased review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70(19): 1699–1706.
19. Orlova O.R., Timerbaeva S.L., Xatkova S.E., Kotlyarov V.V., Korenko L.A., Zalyalova Z.A., Falkovskiy I.V., Batisheva T.T., Gribanov I.I., Kurenkov A.L., Artemenko A.R., Soyxer M.I., Krasavina D.A., Misikov V.K., Kostenko E.V., Mingazova L.R., Soyxer M.G., Surovix S.V., Korenko L.A., Antipova L.N., Antipenko E.A., Shperling L.P. Primenenie preparata Disport (Botulinicheskiy toksin tipa A) dlya lecheniya lokalnogo mishechnogo gipertonusa pri fokalnix distoniyax, spastichnosti i drugix mishechno-tonicheskix sindromax (Medisinskaya texnologiya). M., 2012; 105s.
20. Dressler D., Mander G., Fink K. Measuring the potency labeling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin(®)) in an LD50 assay. J Neural Transm (Vienna) 2012; 119(1): 13–15.3.
